SDC1 and plasma cell myeloma: Notably, in preclinical studies, disruption of the heparanase/syndecan-1 axis by roneparstat was strongly correlated with the inhibition of multiple processes critical in multiple myeloma development and progression including growth, angiogenesis, dissemination, and bone disease-associated osteolysis, a major cause of morbidity in these patients [92,165,196].